Edition:
United States

Key Developments: Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

44.71USD
4:01pm EDT
Change (% chg)

$0.49 (+1.11%)
Prev Close
$44.22
Open
$44.39
Day's High
$44.71
Day's Low
$44.25
Volume
828,553
Avg. Vol
1,154,977
52-wk High
$44.78
52-wk Low
$32.18

Search Stocks

Latest Key Developments (Source: Significant Developments)

Baxter International Inc Initiates Voluntary Nationwide Recall Of One Lot Of IV Solution Due To The Potential For Leaking Containers, Particulate Matter And Missing Port - FDA
Wednesday, 29 Jul 2015 08:00pm EDT 

Baxter International Inc:Says it is voluntarily recalling one lot of intravenous (IV) solution to the hospital/user level due to the potential for leaking containers, particulate matter and missing port protectors. Baxter was made aware of these issues through customer complaints - FDA.Says Leaking containers, particulate matter and missing port protectors could result in contamination of the solution.Says If not detected, this could lead to a bloodstream infection or other serious adverse health consequences.Says Injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver.  Full Article

Baxter International Inc declares quarterly dividend
Wednesday, 29 Jul 2015 04:10pm EDT 

Baxter International Inc:Declares a regular quarterly dividend of $0.115 per Baxter common share.This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.  Full Article

Baxter International Inc gives Q3, H2 2015 outlook; Q3 2015 EPS outlook above analysts' estimates
Wednesday, 29 Jul 2015 04:05pm EDT 

Baxter International Inc:Expects sales growth of approximately 3 percent in both Q3 2015 and H2 2015.Expects Q3 2015 earnings from continuing operations, before special items, of $0.29 to $0.31 per diluted share and $0.58 to $0.62 per diluted share for H2 2015.Q3 2015 revenue of $2.448 bln and EPS of $0.27 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc enters into material definitive agreement - Form 8-K
Thursday, 2 Jul 2015 03:19pm EDT 

Baxter International Inc:Entered into separation and distribution agreement with Baxalta Incorporated.Pursuant to which Baxter agreed to transfer its research-based pharmaceuticals business to Baxalta and about 80.5 pct of outstanding stock of Baxalta to Baxter shareholders in a distribution (the “Distribution”).Distribution was made on July 1, to Baxter shareholders of record as of close of business on June 17.  Full Article

Baxter International Inc prices private placement notes offering
Friday, 19 Jun 2015 08:00am EDT 

Baxter International Inc:Prices $5 billion private placement notes offering.Says priced a private placement offering of $375,000,000 of 2.000 pct senior notes due 2018.Priced a private placement offering of $1 billion of 2.875 pct senior notes due 2020.Priced a private placement offering of $500 million of 3.600 pct senior notes due 2022, $1.75 billion of 4.000 pct senior notes due 2025.  Full Article

Baxter International Inc receives U.S. FDA approval for 0.9 pct sodium chloride injection
Friday, 15 May 2015 05:26pm EDT 

Baxter International Inc:Says U.S. Food and Drug Administration has approved its supplemental drug application to establish Sabinanigo, Spain, facility as an approved manufacturing site for 0.9 pct sodium chloride injection, USP, for U.S. market.Says approval includes product presentations in 250 mL, 500 mL and 1000 mL.  Full Article

Baxter International declares quarterly dividend
Tuesday, 5 May 2015 08:55am EDT 

Baxter International Inc:Declares a quarterly dividend of $0.52 per Baxter common share.Payable on July 1 to shareholders of record as of June 1.  Full Article

Merrimack Pharmaceuticals and Baxter BioScience announce completion of new drug application submission to U.S. FDA for MM-398
Monday, 27 Apr 2015 07:00am EDT 

Merrimack Pharmaceuticals Inc and Baxter International Inc:Jointly says Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration (FDA).Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.Merrimack requested priority review of the MM-398 NDA by the FDA.FDA and European Medicines Agency have granted MM-398 orphan drug designation for patients with metastatic pancreatic cancer.Enters into an exclusive licensing agreement to develop and commercialize MM-398 outside of the United States.PharmaEngine, Inc. (Taipei, Taiwan) holds the rights to commercialize MM-398 in Taiwan.  Full Article

Baxter International Inc gives Q2 2015 guidance; EPS guidance below analysts' estimates
Thursday, 23 Apr 2015 07:00am EDT 

Baxter International Inc:Expects Q2 2015 sales growth of about 1 pct, excluding the impact of foreign currency.Including the impact of foreign currency, the company expects Q2 2015 sales to decline about 9 to 10 pct.Expects Q2 2015 earnings from continuing operations, before special items, of $0.92-$0.96 per diluted share.Q2 2015 guidance excludes about $0.08 per diluted share of projected intangible amortization expense.Reconciling for the inclusion of intangible asset amortization results in expected GAAP earnings of $0.84 to $0.88 per diluted share, before other special items, for the quarter.Q2 2015 revenue of $3.92 bln and EPS of $1.01 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc initiates voluntary recall of select lots of IV solutions
Tuesday, 14 Apr 2015 08:00pm EDT 

Baxter International Inc:Announced it is voluntarily recalling select lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter.Intravenous administration of a solution containing sterile particulate matter lead to adverse health consequences.The extent and severity of harm depends on the size, number, and composition of the foreign material, and patient’s underlying medical condition.In the absence of in-line filtration, these particles cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization.In high-risk patients this lead to serious adverse health consequences.  Full Article

BRIEF-Baxter execs say "transformative M&A is not in the cards" right now

* Execs say "transformative M&A is not in the cards" right now - Conf call Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Search Stocks